Bausch Health Companies Inc. (BHC) stock rallied over 2.97% intraday to trade at $7.27 a share on NYSE. The stock opened with a gain of 3.27% at $7.05 and touched an intraday high of $7.28, rising 2.97% against the last close of $7.06. The stock went to a low of $6.88 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue8.43 Billion
5Y Sales Change-2.70%
Fiscal Year Ends2021-12-30
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Bausch Health Companies Inc. (NYSE: BHC) stock price is $7.27 as of the last check on Thursday, June 23. During the trading session, BHC stock reached the peak price of $7.28 while $6.88 was the lowest point it dropped to.
The NYSE listed BHC is part of Pharmaceuticals industry that operates in the broader Health Care sector. Bausch Health Companies Inc. , together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology.
Mr. Joseph C. Papa
Chairman & CEO
Ms. Christina M. Ackermann
Exec. VP, Gen. Counsel & Head of Commercial Operations
Mr. Paul S. Herendeen
Exec. VP and Advisor to Chairman & CEO
Mr. Thomas J. Appio
Pres & Co-Head Bausch + Lomb/International
BHC stock traded closed the last session at $7.27, which is $0.21 or 2.97% lower than its previous close of $7.06. BHC's current trading price is 3.71% lower than its 52-week high of $30.30 where as its distance from 52-week low of 7.01% is -76.01%.
Number of BHC employees currently stands at -. BHC operates from 2150 St. ElzEar Boulevard West, Laval, QC H7L 4A8, Canada.
Official Webiste of $BHC is: https://www.bauschhealth.com
BHC stock volume for the day was 5,487,007 shares while in the previous session number of BHC shares traded was 5,506,000 . The average number of BHC shares traded daily for last 3 months was 6.85 Million.
The percentage change in BHC stock occurred in the recent session was 2.97% while the dollar amount for the price change in BHC stock was $0.21.
In the recent session, the day high for BHC stock was $7.28 while the low for BHC stock touched on the day was $6.88.
The market value of BHC currently stands at 2.6 Billion with its latest stock price at $7.27 and 360.8 Million of its shares outstanding.